BL-B01D1 plus immunotherapy for advanced lung and throat cancers
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced lung cancer (NSCLC) or nasopharyngeal cancer that has spread or cannot be removed by surgery.
- You should be at least 18 years old and have a life expectancy of at least 3 months.
- Your daily activity level should be good (ECOG 0 or 1) – meaning you are fully active or only slightly limited.
- You must be able to provide a small sample of your tumor tissue from a past biopsy or surgery.
- You should not have had other cancer treatments within the last 4 weeks (or 6 weeks for certain drugs).
- You must not have certain serious heart, lung, or autoimmune conditions, or uncontrolled infections, diabetes, or high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
This trial tests a new drug, BL-M24D1, for people with advanced non-small cell lung cancer or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.